About Amyotrophic lateral sclerosis (ALS)
1 in 300 people will be diagnosed with ALS.
Every 90 minutes someone in the U.S. is diagnosed with ALS.
ALS is a brutal, terminal disease.
As ALS progresses, the brain begins to lose its ability to communicate with the body’s muscles, leaving the person unable to walk, to talk, and eventually, to breathe.
ALS takes aways independence & dignity.
ALS is a fatal disease and people are generally given a life expectancy of 2 to 5 years after diagnosis.
Living with ALS can be financially, emotionally, and mentally burdensome. The financial challenges are staggering, with the cost of living with ALS exceeding $200,000 per year, far beyond what insurance typically covers.
About 90% of ALS cases occur without any known family history or genetic cause.
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease and outside the US as Motor Neuron Disease (MND) or Charcot’s Disease, is a progressive neurodegenerative disease that attacks motor neurons in the brain (upper motor neurons) and spinal cord (lower motor neurons) and affects muscle function.
The motor neurons control the movement of various voluntary muscles including the diaphragm. Associated with the loss of the ability of motor neurons to function in ALS, the various muscles cells waste away (atrophy), resulting in increased muscle weakness. Ultimately, accumulated loss of motor neurons makes it impossible for voluntary control of normal muscle function.
Symptoms of ALS can include twitching and cramping of muscles (called fasciculation), stiffness in muscles (spasticity), increasing loss of motor control in hands and arms and legs, weakness and fatigue, slurred or thick speech and difficulty breathing or swallowing.
In most cases, ALS patients do not typically experience significantly impaired sensory neural functioning, intellectual reasoning, vision or hearing. Eye and bladder muscles, along with sexual function and drive, are not normally affected.
ALS is diagnosed using a variety of tests and examinations, including laboratory tests, muscle and nerve biopsy, spinal tap, X-rays, MRI’s and electrodiagnostic evaluation of axon function.
Currently there is only a single therapy approved for treating ALS progression – the drug Rilutek (riluzole) with the accepted, modest benefit estimated to be a three month extension in patient survival.